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We examined the incidence, risk factors, treatment, and clinical outcomes of extramedullary relapse (EMR) in
961 acute leukemia patients undergoing HLA-haploidentical hematopoietic stem cell transplantation (haplo-
HSCT) between 2002 and 2013. Multiple control subjects were selected at random from the same cohort and
matched to EMR cases for diagnosis, disease status at HSCT, age at the time of the HSCT, and year of HSCT.
Forty patients exhibited EMR, with a median time to EMR of 207 days. The cumulative incidence of EMR was
4.0% at 3 years, and the incidence was higher in acute lymphoblastic leukemia patients compared with acute
myeloid leukemia patients (5.6% versus 2.4%). In the multivariate analysis, nonecomplete remission (CR)
status at HSCT (hazard ratio [HR] ¼ 4.6; P ¼ .018) and nonechronic graft-versus-host disease after HSCT
(HR ¼ 3.2; P < .001) were the independent risk factors for EMR after haplo-HSCT. Twenty-seven patients
received combination treatments, and the proportion of patients who achieved CR was higher than those who
received single treatment. Multifocal involvement at EMR (HR ¼ 2.7; P ¼ .024) and non-CR after EMR
treatments (HR ¼ 4.6; P < .001) were the independent risk factors for poor survival rates among EMR
patients. We found that graft-versus-leukemia effect may help to prevent EMR after haplo-HSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION progress has been made in the ﬁeld of HLA-haploidentical
Allogeneic hematopoietic stem cell transplantation
(HSCT) is one of the most effective treatments for hemato-
logical malignancies, helping to achieve long-term remission
and potentially curing many patients. Although signiﬁcant
progress has been made in allogeneic HSCT, post-transplant
relapse remains one of the most important causes of trans-
plant failure, and extramedullary relapse (EMR) accounts for
a substantial part of total relapses. Some researchers have
reported the incidence of EMR is .65% to 20% for patients who
receive allogeneic HSCT [1,2].
Although risk factors and clinical outcomes for post-HSCT
EMR have been described in acute leukemia patients,
most studies enrolled HLA-identical sibling donors or
HLA-unrelated donor HSCT recipients [3-5]. Considerabledgments on page 2028.
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ty for Blood and Marrow Transplantation.HSCT (haplo-HSCT) over the past 2 decades, and the
haploidentical donor has become a promising alternative
donor source for patients lacking an HLA-identical sibling
donor. Despite the fact that haplo-HSCT may be associated
with a potent graft-versus-leukemia (GVL) effect, some
patients still develop EMR after transplantation. Yoshihara
et al. [6] reported 9 haplo-HSCT recipients who developed
post-HSCT EMR; however, the small sample size of EMR
patients might preclude stable estimations. Thus, the
characteristic patterns of EMR after haplo-HSCT remain
unknown. Therefore, we used both a retrospective cohort
study design and a nested case-control approach [7] to
investigate the incidence, risk factors, treatment, and clinical
outcomes of EMR after haplo-HSCT.METHODS
Patients
A total of 961 consecutive patients underwent haplo-HSCT for acute
leukemia between January 2002 and February 2013 at the Institute of
Hematology, Peking University. Medical records maintained at the Institute
were the primary source of data for the current study. Patients who were
Table 1
Characteristics of AML Patients
Characteristics Control Group
(n ¼ 70)
EMR Group
(n ¼ 14)
P
Median age at HSCT, yr
(range)
26 (9-49) 27 (10-48) .513
Gender, n (%)
Male 51 (72.9) 8 (57.1) .336
Female 19 (27.1) 6 (42.9)
Disease status at
transplantation, n (%)
CR 65 (92.9) 13 (92.9) 1.000
Non-CR 5 (7.1) 1 (7.1)
Poor cytogenetic risk, n (%) 7 (10.0) 2 (14.3) .641
Hyperleukocytosis at
diagnosis, n (%)
11 (15.7) 1 (7.1) .681
EM leukemia before
HSCT, n (%)
5 (7.1) 3 (21.4) .125
Chemotherapy
resistance, n (%)
35 (50.0) 4 (28.6) .142
Donorerecipient gender
match, n (%)
Maleemale 27 (38.6) 5 (35.7) .165
Maleefemale 11 (15.7) 1 (7.2)
Femaleemale 24 (34.3) 3 (21.4)
Femaleefemale 8 (11.4) 5 (35.7)
Donorerecipient
relation, n (%)
Fatherechild 17 (24.3) 4 (28.6) .224
Motherechild 13 (18.6) 5 (35.7)
Siblingesibling 35 (50.0) 4 (28.6)
Childeparent 1 (1.4) 1 (7.1)
Other 4 (5.7) 0 (.0)
Number of HLA-A, -B, -DR
mismatches, n (%)
1 6 (8.6) 3 (21.4) .160
2 29 (41.4) 3 (21.4)
3 35 (50.0) 8 (57.2)
Grafts, n (%)
BM þ peripheral blood 69 (98.6) 14 (100.0) 1.000
BM 1 (1.4) 0 (.0)
Conditioning regimen, n (%)
Chemotherapy 69 (98.6) 14 (100.0) 1.000
TBI þ chemotherapy 1 (1.4) 0 (.0)
Acute GVHD, n (%)
Negative 27 (38.6) 7 (50.0) .563
Grades I-II 39 (55.7) 6 (42.9)
Grades III-IV 4 (5.7) 1 (7.1)
cGVHD
Negative 32 (45.7) 10 (71.4) .231
Limited 16 (22.9) 2 (14.3)
Extensive 22 (31.4) 2 (14.3)
Year of HSCT, n (%)
Before 2009 34 (48.6) 4 (28.6) .170
2009 or later 36 (51.4) 10 (71.4)
Median mononuclear
cells, 108/kg (range)
7.8 (4.2-13.7) 7.8 (5.7-10.4) .784
Median CD34þ
counts, 106/kg (range)
2.2 (.3-7.9) 2.9 (1.0-8.3) .282
Median duration of
follow-up, yr (range)
2.2 (.2-9.6) 1.3 (.7-2.8) .052
None of the EMR patients was diagnosed as acute mixed lineage leukemia.
The criterion for statistical signiﬁcance was P < .05.
Table 2
Characteristics of ALL Patients
Characteristics Control Group
(n ¼ 126)
EMR Group
(n ¼ 26)
P
Median age at HSCT, yr
(range)
18 (3-56) 18 (2-53) .321
Gender, n (%)
Male 79 (62.7) 17 (65.4) .796
Female 47 (37.3) 9 (34.6)
Disease status at
transplantation, n (%)
CR 110 (87.3) 22 (84.6) .751
Non-CR 16 (12.7) 4 (15.4)
Poor cytogenetic risk, n (%) 36 (28.6) 6 (23.1) .568
Hyperleukocytosis at
diagnosis, n (%)
44 (34.9) 6 (23.1) .242
EM leukemia before
HSCT, n (%)
18 (14.3) 8 (30.8) .081
Chemotherapy
resistance, n (%)
41 (32.5) 6 (23.1) .342
Donorerecipient gender
match, n (%)
Maleemale 37 (29.4) 12 (46.2) .414
Maleefemale 23 (18.2) 4 (15.4)
Femaleemale 39 (31.0) 5 (19.2)
Femaleefemale 27 (21.4) 5 (19.2)
Donorerecipient
relation, n (%)
Fatherechild 44 (34.9) 15 (57.7) .165
Motherechild 49 (38.9) 7 (26.9)
Siblingesibling 29 (23.0) 3 (11.5)
Childeparent 2 (1.6) 1 (3.9)
Other 2 (1.6) 0 (.0)
Number of HLA-A, -B, -DR
mismatches, n (%)
1 14 (11.1) 4 (15.4) .677
2 49 (38.9) 8 (30.8)
3 63 (50.0) 14 (53.8)
Grafts, n (%)
BM þ peripheral blood 123 (97.6) 26 (100.0) 1.000
Peripheral blood 2 (1.6) 0 (.0)
BM 1 (0.8) 0 (.0)
Conditioning regimen, n (%)
Chemotherapy 120 (95.2) 23 (88.5) .183
TBI þ chemotherapy 6 (4.8) 3 (11.5)
Acute GVHD, n (%)
Negative 38 (30.2) 9 (34.6) .346
Grades I-II 69 (54.8) 16 (61.5)
Grades III-IV 19 (15.1) 1 (3.9)
cGVHD
Negative 52 (41.3) 15 (57.7) .305
Limited 32 (25.4) 5 (19.2)
Extensive 42 (33.3) 6 (23.1)
Year of HSCT, n (%)
Before 2009 56 (44.4) 12 (46.2) .873
2009 or later 70 (55.6) 14 (53.8)
Median mononuclear
cells, 108/kg (range)
7.8 (3.0-17.2) 7.8 (3.9-10.9) .688
Median CD34þ
counts, 106/kg (range)
2.5 (.6-9.4) 2.6 (.8-7.7) .487
Median duration of
follow-up, yr (range)
1.2 (.1-10.3) 1.3 (.1-8.9) .811
None of the EMR patients was diagnosed as acute mixed lineage leukemia.
The criterion for statistical signiﬁcance was P < .05.
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achieved complete remission (CR) before HSCT and who developed EMR
after HSCT were considered as EMR cases. For each EMR patient, a set of
control subjects (4 to 5) was randomly selected from the same cohort at the
time at which EMR occurred (“risk-set sampling”) [8] and was matched
according to the following criteria: diagnosis, disease status at HSCT (CR or
non-CR), age at the time of the HSCT (5 years), and year of the HSCT (2
years). Forty patients with EMR and 196 matched control subjects were
included in the analysis; 36 EMR patients were matched with 5 control
subjects and the other 4 patients were matched with 4 control subjects
(Tables 1 and 2). The study protocol was approved by the ethics committee
at Peking University People’s Hospital. Informed consent was obtained
according to the Declaration of Helsinki.Transplant Regimens
The major preconditioning treatment consisted of cytarabine (4 g/
[m2$day] for 2 days), busulfan (4 mg/[kg$day] administered orally for 3
days before January 2008 or 3.2 mg/[kg$day] administered intravenously
for 3 days after January 2008), cyclophosphamide (1.8 g/[m2$day] for 2
days), and simustine (250 mg/m2 for 1 day), along with rabbit antithy-
mocyte globulin (ATG; thymoglobulin; rabbit ATG from Imtix Sangstat,
Lyon, France; 2.5 mg/[kg$day] for 4 days). Some patients (n ¼ 10) also
received total body irradiation (TBI) as part of the conditioning regimens.
The granulocyte colony-stimulating factor mobilized, fresh, and unmanip-
ulated bone marrow and/or peripheral blood harvests were infused into
the recipients on the day of collection. Granulocyte colony-stimulating
Figure 1. Cumulative incidence of EMR for AML and ALL patients.
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6 after transplantation until their WBC counts exceeded 2  109 cells/L for
3 consecutive days. Additionally, all patients received cyclosporine A,
mycophenolate mofetil, and short-term methotrexate for graft-versus-host
disease (GVHD) prophylaxis [9]. Prophylactic, interventional, and thera-
peutic donor lymphocyte infusion (DLI) after transplantation was
performed as previously reported [10]. Prophylaxis of central nervous
system (CNS) leukemia before HSCT consisted of intrathecal chemotherapy
for at least 6 doses for acute lymphoblastic leukemia (ALL) patients, at least
4 doses for acute myeloid leukemia (AML) patients with WBC counts >
100  109 cells/L at diagnosis, and at least 2 doses for other AML patients
during induction chemotherapy and consolidation chemotherapy.
Donor Selection and HLA Typing
Patients without a suitable closely HLA-matched unrelated donor,
namely, with >8 of 10 matching HLA-A, -B, -C, -DR, and -DQ loci, and 5 of 6
or 6 of 6 matching HLA-A, -B, and DR loci, were eligible for haplo-HSCT if an
HLA-identical sibling donor was unavailable as a ﬁrst treatment option. To
determine HLA-A and HLA-B status, low-resolution DNA techniques were
used. High-resolution techniques were used for HLA-DRB1 typing. Each
patient with a haploidentical related donor received stem cells from a family
member who shared 1 HLA haplotype with the patient but differed to a
variable degree for the HLA-A, -B, and -D antigens of the haplotype not
shared. Apart from each donorerecipient pair, HLA typing was performed
for parents and offspring to be strictly analyzed to guarantee true haploid
genetic background [11].
Deﬁnitions
EMR included cases of both isolated EMR and concurrent bone marrow
relapse (BMR), and BMR was deﬁned as the reappearance of blasts in the
peripheral blood or more than 5% blasts in the BM smear. In isolated EMR
patients, the evaluation of BM status (including morphology, cytogenetics,
and molecular examination) had to reveal CR and chimerism study had to
reveal full-donor chimerism. EMR was identiﬁed on physical examination
and/or by imaging studies (computed tomography, magnetic resonance
imaging, or positron emission tomography), and pathological conﬁrmation
was performed whenever possible but was not necessarily required. CNS
relapse was diagnosed when leukemic cells were identiﬁed in the cere-
brospinal ﬂuid.
Adverse cytogenetics was deﬁned as del(5q) or monosomy 5; mono-
somy 7 or del(7q); abnormal 3q, 9q, 11q, 21q, or 17p; t(6;9); t(9;22); and
complex karyotypes in AML [12] and was deﬁned as t(9;22), t(4;11), t(8;14),
low hypodiploidy-near triploidy, or complex karyotype in ALL [13]. Hyper-
leukocytosis in cases of AML was deﬁned as a peripheral WBC count of over
100  109 cells/L at diagnosis, B-precursor ALL as a count of over 30  109
cells/L, and T-precursor ALL as a count of over 100  109 cells/L.
Chemotherapy resistance before HSCT was deﬁned as remission
requiring more than 1 course of induction therapy or relapse during
consolidation chemotherapy and inability to achieve CR after reinduction
therapy. The diagnosis of GVHD was made in accordance with accepted
international criteria [14,15]. For isolated EMR patients, CR was deﬁned as
disappearance of all clinical signs of EM leukemia, conﬁrmed by physical
examination and imaging studies. Particularly for CNS relapse patients, CR
was deﬁned as disappearance of leukemia cells in cerebrospinal ﬂuid. For
EMR with concurrent BMR patients, CR was deﬁned as presence of less than
5% blast cells in normocellular BM, peripheral blood cell counts showing at
least 1.5  109 neutrophils/L, and disappearance of all clinical signs of EM
leukemia. Overall survival (OS) was deﬁned as the time from transplantation
to death from any cause.
Statistical Analysis
In the cohort analysis, competing risk analysis was performed to
calculate the cumulative incidence of EMR [16], treating death without EMR
as the competing event for EMR. The time to risk was computed from the
date of haplo-HSCT to the date of onset of EMR, the date of last contact, or
the date of death, whichever came ﬁrst. The log-rank test was used to
compare the various subpopulations.
In the nested case-control analysis, continuous variables were compared
using the Mann-Whitney U test, and categorical variables were compared
using chi-square and Fisher’s exact tests. Survival probabilities were esti-
mated using the Kaplan-Meier method. Hazard ratios (HRs) for EMR were
estimated from univariate and multivariate competing risk regression ana-
lyses [17], and factors included in the regression model were age, sex,
diagnosis, adverse cytogenetics, hyperleukocytosis, chemotherapy resis-
tance before HSCT, a history of EM leukemia before HSCT, disease status at
transplantation (CR versus non-CR), HLA disparity (1 locus versus 2 loci),
donorerecipient gender matching (femaleemale versus others), acute
GVHD, and chronic GVHD (cGVHD). HRs for OS of EMR patients wereestimated from univariate and multivariate Cox regression analyses. The
factors studied in the Cox regression model were multifocal involvement at
EMR (2 versus 1), therapy regimen for EMR (combination versus single
treatment), GVHD after therapy (yes versus no), and achievement of CR after
therapy (yes versus no).
All factors with P < .1 in the univariate analysis were included in the
multivariate regression, and P < .05 was considered to be statistically
signiﬁcant. All reported P values were based on 2-sided hypothesis tests.
Data analyses were primarily conducted using SPSS software (SPSS Inc.,
Chicago, IL), whereas the R software package (version 2.6.1; http://www.r-
project.org) was used for competing risk analysis.RESULTS
Incidence and Characteristics of EMR
During the follow-up period, 40 patients exhibited EMR
with a median time from HSCT to EMR of 207 days (range, 10
to 2809), and the detail of each EMR case is described in
Supplementary Table 1. Fourteen patients had isolated EMR,
and 26 developed EMR with concurrent BMR. Of these 26
cases, 11 patients who initially had EMR later developed
BMR, 5 patients with BMR later developed EMR, and the
remaining 10 patients experienced EMR and BMR almost
simultaneously.
The 3-year cumulative incidence of EMR was 4.0% (95%
conﬁdence interval [CI], 2.4% to 5.6%). The 3-year cumulative
incidences of isolated EMR and EMR with concurrent BMR
were 1.8% (95% CI, .8% to 2.8%) and 2.2% (95% CI, 1.8% to 2.6%),
respectively. The 3-year cumulative incidence of ALL patients
was 5.6% (95% CI, 2.9% to 8.3%), which was higher than that of
AML patients (2.4%; 95% CI, .8% to 4.0%; P ¼ .062) (Figure 1).
The EM sites involved in the relapse varied, including CNS
(n¼ 19), bone (n¼ 5), testis (n¼ 4), breast (n¼ 4), soft tissue
(n ¼ 4), lymph nodes (n ¼ 4), mediastinum (n ¼ 4), perito-
neum (n¼ 2), ovary (n¼ 1), and gastrointestinal tract (n¼ 1).
Multifocal involvement at EMR (2) was observed in 8
patients. Eleven patients had a history of EM leukemia before
HSCT, and 6 of them relapsed in the same site as the previous
leukemia.Risk Factors of EMR
For overall EMR of acute leukemia patients, non-CR status
at transplantation (HR ¼ 4.6; 95% CI, 1.3 to 16.3, P ¼ .018) and
non-cGVHD after transplantation (HR ¼ 3.2; 95% CI, 1.7 to
Table 3
Univariate and Multivariate Analyses of the Factors associated with EMR
Variable Univariate
Analysis
Multivariate
Analysis
HR 95% CI P HR 95% CI P
Age
<Median 1.0 .597
Median .8 .4-1.7
Sex
Male 1.0 .862
Female .9 .5-1.9
Diagnosis
AML 1.0 .806
ALL 1.1 .5-2.4
Adverse cytogenetics
No 1.0 .941
Yes 1.0 .4-2.3
Hyperleukocytosis
No 1.0 .293
Yes .6 .3-1.5
Chemotherapy resistance
before HSCT
No 1.0 .390
Yes 2.4 .3-17.9
EM leukemia before HSCT
No 1.0 1.0 .060
Yes 3.0 .9-9.7 .062 3.7 .9-14.6
Disease status at HSCT
CR 1.0 .016 1.0 .018
Non-CR 4.8 1.3-16.9 4.6 1.3-16.3
HLA disparity
1 locus 1.0 .118
2 loci .5 .2-1.2
Donorerecipient gender
matching
Others 1.0 .123
Femaleemale .5 .2-1.2
Acute GVHD
Yes 1.0 .367
No 1.3 .7-2.5
cGVHD
Yes 1.0 .003 1.0 <.001
No 2.9 1.5-5.9 3.2 1.7-6.2
Bold font indicates statistical signiﬁcance, and the criterion for statistical
signiﬁcance was P < .05.
Figure 2. Kaplan-Meier estimates of overall survival: P ¼ .523 (isolated EMR
versus EMRþBMR), P ¼ .169 (isolated EMR versus isolated BMR), P ¼ .355
(EMRþBMR versus isolated BMR); P ¼ .001 (isolated EMR versus non-EMR/
BMR), P < .001 (isolated BMR versus non-EMR/BMR), and P < .001
(EMRþBMR versus non-EMR/BMR).
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haplo-HSCT in multivariate analysis (Table 3). For ALL
patients, non-CR status at transplantation (HR ¼ 6.1; 95% CI,
1.1 to 34.6; P ¼ .042), a history of EM leukemia before
transplantation (HR ¼ 3.8; 95% CI, 1.5 to 9.2; P ¼ .004), and
non-cGVHD after transplantation (HR ¼ 2.9; 95% CI, 1.3 to
6.5; P ¼ .009) were the independent risk factors for EMR in
multivariate analysis. For AML patients, only non-cGVHD
after transplantation was found to be independently associ-
ated with EMR (HR ¼ 4.5; 95% CI, 1.2 to 16.4; P ¼ .023) in
multivariate analysis.Comparison between EMR and BMR
In the control group, 46 patients experienced isolated
BMR with a median time from HSCT to isolated BMR of 210
days (range, 47 to 1392). The proportion of patients who
were chemotherapy resistant before HSCT was signiﬁcantly
lower in EMR group as compared with the isolated BMR
group (25.0% versus 65.2%, P < .001), whereas the other
variables were comparable between the EMR and isolated
BMR group (Supplementary Table 2).
One EMR patient (2.5%) and 6 isolated BMR patients
(13.0%) received prophylactic DLI before relapse (P ¼ .116); 7
EMR patients (17.5%) and 6 isolated BMR patients (13.0%)who were minimal residual disease positive after HSCT
received interventional DLI (P ¼ .565). The 3-year probabili-
ties of OS in cases of isolated EMR, EMR with concurrent
BMR, and isolated BMR groups were comparable (Figure 2).
Treatment and Clinical Outcomes of EMR Patients
Two EMR patients refused any treatment and died of
relapse. Nineteen patients who developed CNS relapse were
all treated with intrathecal chemotherapy; in addition, 10 of
these patients were also treated with cranial irradiation,
and 8 patients with concurrent BMR received systematic
chemotherapy and DLI. Among another 19 patients, 13
received systematic chemotherapy, 12 received DLI, 10
received irradiation, and 3 received local surgery. Twenty-
seven patients received combination treatments (2 types
of treatment), and the proportion of patients who achieved
CR was higher than those who received single treatment
(63.0% versus 36.4%, P ¼ .167), although the difference was
not statistically signiﬁcant. Twelve patients developed GVHD
after treatment for EMR (skin, n ¼ 10; gastrointestinal tract,
n ¼ 6; liver, n ¼ 3; oral cavity, n ¼ 2), and the proportion of
patients who achieved CRwas signiﬁcantly higher in patients
who developed GVHD compared with those without GVHD
(83.3% versus 39.3%, P ¼ .011).
Twenty-one EMR patients achieved CR after treatment. To
date, 9 of them still survive, whereas the other 12 died (9
died of leukemia recurrence, 2 died of infection, and 1 died of
GVHD). In multivariate analysis, multifocal involvement at
EMR (HR ¼ 2.7; 95% CI, 1.1 to 6.4; P ¼ .024) and non-CR after
EMR treatments (HR¼ 4.6; 95% CI, 2.0 to 10.5; P< .001) were
the independent risk factors for poor OS among EMR
patients.
DISCUSSION
Although several studies have identiﬁed the characteris-
tics of post-HSCT EMR, to the best of our knowledge, this
study is the largest reported series of EMR after haplo-HSCT
in acute leukemia patients. We observed the 3-year cumu-
lative incidence of EMR was 4% after haplo-HSCT, and the
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that in AML patients. In addition, our analyses also revealed
that cGVHD can decrease the risk of EMR in haplo-HSCT re-
cipients, and development of GVHD after treatment of EMR
may help to achieve CR.
Several studies have identiﬁed the correlation between
cGVHD and EMR after HSCT; however, results were contro-
versial. Some authors observed a higher incidence of cGVHD in
patients with EMR compared with BMR patients [18], and
occurrence of EMR was higher in patients suffering from
extensive cGVHD [19]. Other authors reported the incidence of
EMR did not differ between patients with cGVHD and patients
without cGVHD, and cGVHDcouldnotdecrease the riskof EMR
[2,4,5,20]. Someof the EMsites, such as theCNS and testis,may
act as “sanctuary” locations for leukemic cells, thus providing
protection from both cytotoxic conditioning regimens and
immune surveillance throughGVLeffects [4,5]. Cytotoxic CD8þ
T cells, the main mediators of the GVL effect, are much more
concentrated in the BM compared with that in peripheral tis-
sues [18]. In addition, recruitment of accessory cells necessary
to achieve efﬁcient local antileukemic activitymay bedeﬁcient
in sites of EMR [20]. However, some authors reported that
acute leukemia patients who develop EMR after HSCT were
treated with DLI, developed GVHD, and achieved complete
resolution [21-23], and these reports provided evidence for the
GVL effects toward EMR. In our studies, we found that cGVHD
can decrease the risk of EMR in haplo-HSCT recipients. In
addition,we observed the occurrence of GVHD after treatment
for EMR can help to achieve CR, and EMR patients who ach-
ieved CR had better OS. These are interesting results that
suggest the potent GVL effect after haplo-HSCT might be
responsible for better eradication of EM leukemia cells.
Several studies have reported adverse cytogenetics,
hyperleukocytosis at diagnosis, male gender, TBI, and the
source of peripheral blood stem cell (PBSC) as risk factors for
EMR after HSCT [2-5]; however, in our study we did not
observe the correlation between these variables and occur-
rence of EMR. We had reported that adverse cytogenetics
and hyperleukocytosis were not associated with relapse after
haplo-HSCT [24], which possibly suggests haplo-HSCT may
help to overcome the poor prognostic signiﬁcance of these
factors at diagnosis in acute leukemia patients. Ge et al. [2]
observed that male gender had a high frequency of EMR
and there was a relatively high incidence of EMR with testis
leukemia subtype in the cohort (5/26); however, only 10% of
patients developed testis leukemia in our cohort. Although
some authors observed that patients who received TBI or
PBSCs had a higher risk of EMR, these patients had other risk
factors for EMR (such as advanced stage of the disease and a
history of EM leukemia before HSCT) [2], and other studies
failed to observe the correlation between these 2 variables
and EMR [4,18,25]. In our study the number of patients who
received TBI or PBSCs was too small to permit further
investigation of the correlation between these 2 variables
and EMR. Consequently, we could not completely exclude the
inﬂuence of TBI and PBSCs on post-HSCT EMR.
There have been few studies on the correlation between
chemotherapy resistance before HSCT and post-HSCT EMR.
In our study, we observed the proportion of patients who
were chemotherapy resistant was signiﬁcantly lower in EMR
groups compared with that in isolated BMR groups. This
suggests that although some patients were evaluated as
having achieved CR before HSCT, asymptomatic EM sites
might not be routinely studied clinically, and hence, EM
leukemia before HSCT may be underreported. We also foundthat a history of EM leukemia before transplantation seems
more common in EMR group. Therefore, it is important to
establish new methods with higher sensitivity that can
detect the presence of EM leukemia better before HSCT.
Although Lee et al. [3] observed no signiﬁcant difference
in postrelapse survival between patients with isolated BMR
and EMR with or without BM involvement, other authors
observed that survival was signiﬁcantly better in patients
with isolated EMR [4-6,18]. We also observed a better prog-
nosis in patients with isolated EMR compared with those
with BMR or systemic relapse, and the trend suggested the
difference would have been more signiﬁcant if more patients
were studied. Some authors suggested that in case of isolated
EMR, persistence of donor hematopoiesis in the recipient’s
BM may be responsible for increased susceptibility to treat-
ments [5]. Thus, the strategy to prevent systemic relapse is
important to improve the outcomes.
There has been no standardized therapeutic strategy for
post-HSCT EMR. Although several studies have shown that
local radiotherapy could offer some patients long-term sur-
vival, most patients developed systemic relapse [26]. Shi
et al. [5] observed patients treated with combination therapy
involving local surgery, radiotherapy, chemotherapy, and DLI
achieved longer survival compared with those who received
single therapy. However, Harris et al. [4] did not observe the
advantage of combination strategies based on chemotherapy.
In our study, although the combination treatment seemed to
increase the CR rate, it could not improve OS. Some authors
suggested that systemic chemotherapy may also abrogate
the effector cells on GVL [6]; in addition, the infection and
GVHD may lead to nonrelapse mortality. Thereafter, some
authors suggested that gemtuzumab ozogamicin [27] or
hypomethylating agents [28] may further improve the clin-
ical outcomes of post-HSCT EMR patients, but it should be
conﬁrmed by further studies.
ATG plays a critical role in our protocol of GVHD pro-
phylaxis; however, we also observe that cGVHD may help to
decrease the risk of EMR. Because all patients received ATG
for GVHD prophylaxis in this study, we did not know
whether ATG increases the risk of sanctuary site relapse.
However, data from 6 studies including 568 patients sug-
gested the incidence of relapsewas not signiﬁcantly different
between ATG and non-ATG groups [29]. The protective effect
of ATG on cGVHD included the limited form, but more so the
extensive form, of the disease [30], and some authors
observed that only limited cGVHDwas associated with lower
relapse rates and improved survival [31]. In addition, some
authors also observed the antileukemic activity of ATG by
measuring apoptosis in myeloid and lymphatic leukemia cell
lines and primary leukemia cells [32]. Thus, no evidence
suggested that ATGmay increase the risk of EMR after haplo-
HSCT. Further studies including haplo-HSCT recipients
receiving other protocols of GVHD prophylaxis (such as post-
transplantation high-dose cyclophosphamide) may help to
further investigate the inﬂuence of ATG on post-HSCT EMR.
This study has certain limitations. There were only 40
EMR events, and this relatively small number may not pro-
vide sufﬁcient statistical power to prove the positive effect of
cGVHD on EMR. Therefore, it would be premature to derive
the conclusion that cGVHD could decrease the risk of EMR
after haplo-HSCT. Amulticenter trial with a larger population
may be needed to conﬁrm the characteristics of patients who
develop EMR after haplo-HSCT.
In summary, we found that 3-year cumulative incidence
of EMRwas 4.0% in haplo-HSCT recipients, and non-CR status
X.-D. Mo et al. / Biol Blood Marrow Transplant 20 (2014) 2023e20282028at transplantation and non-cGVHD after transplantation
were the independent risk factors for EMR after haplo-HSCT.
In addition, the GVL effect may help to prevent and eradicate
the EMR after haplo-HSCT, but this needs to be conﬁrmed by
further studies.
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